1. Introduction of Naproxen
Naproxen is one kind of white to light yellow crystal powder and belongs to the classes of Carboxylic Acids (Chiral); Chiral Building Blocks; for Resolution of Bases; Optical Resolution; Synthetic Organic Chemistry; Intermediates & Fine Chemicals; Pharmaceuticals. The IUPAC name is (2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid. In addition, the Classification Code is Analgesic; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-inflammatory; Anti-inflammatory agents, non-steroidal; Antipyretic; Antirheumatic Agents; Cyclooxygenase inhibitors; Drug / Therapeutic Agent; Enzyme Inhibitors; Gout suppressants; Human Data; Mutation data; Peripheral Nervous System Agents; Reproductive Effect; Sensory System Agents. Naproxen can soluble in organic solvents.

2. Properties of Naproxen
Physical properties about Naproxen are:
(1)ACD/LogP: 2.88; (2)ACD/LogD (pH 5.5): 2.135; (3)ACD/LogD (pH 7.4): 0.347; (4)ACD/BCF (pH 5.5): 16.387; (5)ACD/BCF (pH 7.4): 1; (6)ACD/KOC (pH 5.5): 158.568; (7)ACD/KOC (pH 7.4): 2.584; (8)#H bond acceptors: 3; (9)#H bond donors: 1; (10)#Freely Rotating Bonds: 3; (11)Polar Surface Area: 46.53 Å²; (12)Index of Refraction: 1.609; (13)Molar Refractivity: 66.523 cm³; (14)Molar Volume: 192.25 cm³; (15)Polarizability: 26.372 ×10^-24cm³; (16)Surface Tension: 47.465 dyne/cm; (17)Density: 1.198 g/cm³; (18)Flash Point: 154.529 °C; (19)Enthalpy of Vaporization: 69.096 kJ/mol; (20)Boiling Point: 403.888 °C at 760 mmHg.

3. Structure Descriptors of Naproxen
You can still convert the following datas into molecular structure:
(1)SMILES: C[C@@H](c1ccc2cc(ccc2c1)OC)C(=O)O
(2)InChI: InChI=1/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1
(3)InChIKey: CMWTZPSULFXXJA-VIFPVBQEBN
(4)Canonical SMILES: CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O
(5)Isomeric SMILES: C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O

4. Toxicity of Naproxen
The toxicity data is as follows:

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
child	TDLo	oral	2250mg/kg/26W (2250mg/kg)	SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"	British Journal of Rheumatology. Vol. 26, Pg. 210, 1987.
dog	LD50	oral	> 1gm/kg (1000mg/kg)		Yakkyoku. Pharmacy. Vol. 29, Pg. 861, 1978.
dog	LD50	unreported	1gm/kg (1000mg/kg)		Journal of Clinical Pharmacology. Vol. 15, Pg. 311, 1975.
guinea pig	LD50	oral	665mg/kg (665mg/kg)		Archives of Toxicology, Supplement. Vol. 7, Pg. 365, 1984.
hamster	LD50	oral	1400mg/kg (1400mg/kg)		Archives of Toxicology, Supplement. Vol. 7, Pg. 365, 1984.
hamster	LD50	unreported	4110mg/kg (4110mg/kg)		Journal of Clinical Pharmacology. Vol. 15, Pg. 311, 1975.
man	TDLo	oral	54mg/kg (54mg/kg)	GASTROINTESTINAL: NAUSEA OR VOMITING KIDNEY, URETER, AND BLADDER: PROTEINURIS KIDNEY, URETER, AND BLADDER: HEMATURIA	Journal of Toxicology, Clinical Toxicology. Vol. 33, Pg. 173, 1995.
man	TDLo	oral	114mg/kg/10D- (114mg/kg)	BLOOD: CHANGES IN PLATELET COUNT	Journal of Clinical Pharmacology. Vol. 40, Pg. 124, 2000.
man	TDLo	oral	214mg/kg/30D- (214mg/kg)	LIVER: "JAUNDICE, OTHER OR UNCLASSIFIED" LIVER: OTHER CHANGES KIDNEY, URETER, AND BLADDER: OTHER CHANGES IN URINE COMPOSITION	Postgraduate Medical Journal. Vol. 56, Pg. 368, 1980.
man	TDLo	oral	3429mg/kg/35W (3429mg/kg)	VASCULAR: BP ELEVATION NOT CHARACTERIZED IN AUTONOMIC SECTION LUNGS, THORAX, OR RESPIRATION: CYANOSIS	Postgraduate Medical Journal. Vol. 68, Pg. 766, 1992.
mouse	LD50	intraperitoneal	500mg/kg (500mg/kg)		Bollettino Chimico Farmaceutico. Vol. 119, Pg. 600, 1980.
mouse	LD50	intravenous	435mg/kg (435mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: EXCITEMENT	Journal of Pharmacology and Experimental Therapeutics. Vol. 179, Pg. 114, 1971.
mouse	LD50	oral	360mg/kg (360mg/kg)		Farmaco, Edizione Scientifica. Vol. 40, Pg. 334, 1985.
mouse	LD50	subcutaneous	475mg/kg (475mg/kg)		Oyo Yakuri. Pharmacometrics. Vol. 6, Pg. 1039, 1972.
mouse	LD50	unreported	1234mg/kg (1234mg/kg)		Journal of Clinical Pharmacology. Vol. 15, Pg. 311, 1975.
rat	LD50	intraperitoneal	354mg/kg (354mg/kg)		Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 9, Pg. 829, 1978.
rat	LD50	oral	248mg/kg (248mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 41, Pg. 1265, 1991.
rat	LD50	subcutaneous	928mg/kg (928mg/kg)	LUNGS, THORAX, OR RESPIRATION: DYSPNEA	Kiso to Rinsho. Clinical Report. Vol. 17, Pg. 1272, 1983.
women	LDLo	oral	200mg/kg/10D- (200mg/kg)	BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) LUNGS, THORAX, OR RESPIRATION: DYSPNEA KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)"	American Journal of Hematology. Vol. 58, Pg. 142, 1998.
women	TDLo	oral	40mg/kg/2D-I (40mg/kg)	KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)"	Scandinavian Journal of Rheumatology. Vol. 15, Pg. 401, 1986.
women	TDLo	oral	70mg/kg/W-I (70mg/kg)	LIVER: "JAUNDICE, CHOLESTATIC"	New England Journal of Medicine. Vol. 295, Pg. 1201, 1976.
women	TDLo	oral	126mg/kg/3W-I (126mg/kg)	LUNGS, THORAX, OR RESPIRATION: "FIBROSIS, FOCAL (PNEUMOCONIOSIS)" LUNGS, THORAX, OR RESPIRATION: DYSPNEA BLOOD: EOSINOPHILIA	Japanese Journal of Medicine. Vol. 30, Pg. 32, 1991.
women	TDLo	oral	315mg/kg/3W-I (315mg/kg)	BEHAVIORAL: EXCITEMENT GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" GASTROINTESTINAL: NAUSEA OR VOMITING	American Journal of Medicine. Vol. 89, Pg. 526, 1990.
women	TDLo	oral	900mg/kg/9W-I (900mg/kg)	SKIN AND APPENDAGES (SKIN): PHOTOSENSITIVITY: AFTER SYSTEMIC EXPOSURE	Medical Journal of Australia. Vol. 151, Pg. 167, 1989.

5. Physical Properties of Naproxen

Physical Property	Value	Units	Temp (deg C)	Source
Melting Point	153	deg C		EXP
pKa Dissociation Constant	4.15	(none)		EXP
log P (octanol-water)	3.18	(none)		EXP
Water Solubility	15.9	mg/L	25	EXP
Vapor Pressure	1.89E-06	mm Hg	25	EST
Henry's Law Constant	3.39E-10	atm-m3/mole	25	EST
Atmospheric OH Rate Constant	1.16E-10	cm3/molecule-sec	25	EST

6. Preparation of Naproxen
Naproxen can be prepared by 2-(6-Methoxy-2-naphthyl)propenoic acid. This reaction will need reagent H₂, catalyst (+)PF₆(-) and solvents methanol and acetone. The reaction time is 2 hours at reaction temperature of 25 °C.

7. Uses of Naproxen
Naproxen can react with 2-bromo-cyclohexanone to get 2-Oxocyclohexyl 2-(6-methoxy-2-naphthyl)propionat. This reaction will need reagent Et₃N and solvent acetone. The reaction time is 3 hours by heating. The yield is about 58%.

8. Safety information of Naproxen
When you are using this chemical, please be cautious about it as the following: This chemical is harmful if swallowed. During using it, wear suitable protective clothing and gloves.